08/12/2020 - 15:57
- Clarín.com
- Society
The announcement that Argentina will manufacture the coronavirus vaccine carried out by the University of Oxford put the value of the masterful explanation given by Marta Cohen, head of the Department of Histopathology at the Children's Hospital of the town of Sheffield, in the United Kingdom, on the vaccine
The explanation of the Argentine doctor about the encouraging results of the Chadox vaccine went viral on social networks at the end of July.
Cohen is a pediatrician and perinatal practitioner living in Sheffield, UK since 2003 , where she serves as Head of the Department of Histopathology at Children's Hospital. And in a short video of almost three minutes she gave her promising vision.
“The vaccine is also being tested in Brazil and South Africa. The preliminary results were from phase 2. 500 patients were given this vaccine, which is called CHADOX, because it uses adenovirus as a vector. 500 people were given this CHADOX vaccine and another 500 were given the meningococcal vaccine which was called the control group. The people who received the CHADOX vaccine had some local complications, a little headache, but there were no serious complications, which is very important, "said the doctor in the video that was circulated on social networks and WhatsApp.
Cohen is a pathologist, a specialty that is responsible for the study of diseases and biochemical and functional structural changes that underlie disease in cells, tissues and organs.
In front of the AstraZaneca Laboratory, where Argentina manufactured the vaccine against Covid 19. Photo Germán García Adrasti.
“ 91%, with one dose, developed antibodies . However, when they gave him a second dose, 100% of the people who received the CHADOX coronavirus vaccine had antibodies. And these antibodies, the immune response to the coronavirus was seen in two parts: at 14 days they developed what is called the cellular immunity response of T lymphocytes, and at 28 days they developed immunoglobulin G (IgG) antibodies ", he continued the specialist.
According to Cohen, the development of these antibodies "has two very big implications: one is that patients who receive the coronavirus vaccine will probably need two doses, not probably, almost certainly two doses will be needed to generate immunity. And Second, although we know that antibodies last two months, three months, the fact that at 14 days the patients developed cellular immunity, -this is the immunological memory that can remain in the body and that although there are no longer antibodies in the serum , in plasma, can patients have an immune response to defend against coronavirus. "
“ This is very good news, very encouraging , and I couldn't stop sharing it with you,” concluded Cohen.
"The good news is that it won't be expensive."
The doctor assured that " the good news is that the vaccine will not be expensive and they will make donations to make it accessible to developing countries."
"There are already millions of doses prepared to be marketed, but we will have to wait until December or January," explained Cohen in dialogue with Continental radio, and warned that "the pandemic affects everyone."
Cohen admitted that the vaccine being developed at the University of Oxford has some side effects, but said "none were serious."
In phase I / II, the vaccine was shown to be safe and elicited immune responses in 1,000 adult volunteers in the UK. A phase II / III study is underway, involving 50,000 people, of which 5,000 are enrolling in Brazil and 2,000 in South Africa.
JPE AFG
